Beyond Air(US:XAIR)2026-02-13 21:15Revenue Performance - Revenue increased by 105% year-over-year to $2.2 million for the fiscal quarter ended December 31, 2025, compared to $1.1 million for the same period last year[9] - Total revenues for the three months ended December 31, 2025, were $2,194,000, representing a 104% increase from $1,072,000 in the same period of 2024[34] - The company maintained its fiscal year 2026 revenue guidance of $8-10 million[20] Profit and Loss - Gross profit for the quarter increased to $0.3 million, compared to a gross loss of $0.2 million for the same quarter last year[13] - Gross profit for the three months ended December 31, 2025, was $300,000, compared to a gross loss of $215,000 in the same period of 2024[34] - Net loss attributed to common stockholders was ($7.3) million or a loss of ($0.85) per share, compared to a net loss of ($13.0) million or ($2.96) per share for the same quarter last year[16] - Net loss attributable to Beyond Air, Inc. for the three months ended December 31, 2025, was $7,336,000, compared to a net loss of $13,032,000 in the same period of 2024, indicating a 44% improvement[34] - Comprehensive loss attributable to Beyond Air, Inc. for the three months ended December 31, 2025, was $7,311,000, compared to $13,093,000 in the same period of 2024, reflecting a 44% reduction in losses[34] Expenses - Research and development expenses decreased by 19% to $2.4 million compared to $3.0 million for the same quarter last year[14] - Selling, general and administrative expenses decreased by 42% to $4.5 million from $7.7 million in the same quarter last year[14] - Total operating expenses for the three months ended December 31, 2025, were $6,896,000, down from $10,737,000 in the same period of 2024, reflecting a 36% decrease[34] Cash and Assets - Pro forma cash balance was approximately $22.3 million, including net proceeds of approximately $4.5 million from a recent private placement[5] - Total current assets increased to $25,564,000 as of December 31, 2025, from $16,018,000 as of March 31, 2025, marking a 60% growth[32] - Cash and cash equivalents increased to $6,643,000 as of December 31, 2025, from $4,665,000 as of March 31, 2025, showing a 42% increase[32] Liabilities - Long-term debt increased significantly to $21,974,000 as of December 31, 2025, compared to $9,197,000 as of March 31, 2025, representing a 139% rise[32] - Total liabilities rose to $28,488,000 as of December 31, 2025, from $15,721,000 as of March 31, 2025, reflecting an increase of 81%[32] Business Developments - The company signed a binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS, with potential proceeds of up to $32.5 million[1] - The company completed its first sale of LungFit PH systems to a VA Medical Center, creating a potential pathway for future orders[9] - Phase 1a data from the UNO program in solid tumors is set to be presented at the AACR Annual Meeting in April 2026[4] Share Information - The weighted average number of shares outstanding for the three months ended December 31, 2025, was 8,616,860, compared to 4,403,726 for the same period in 2024, indicating a 96% increase in shares[34]